These findings suggest that CD19-DAP12-BB CAR T cells may offer improved persistence, faster tumor clearance, and reduced toxicity, making them a promising alternative to conventional second-generation CAR T therapies for r/r B-ALL. The gene discussed is TYROBP; the disease is neoplasm.